What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?

被引:149
作者
Eisenkop, SM
Spirtos, NM
机构
[1] Womens Canc Ctr, Tarzana, CA 91356 USA
[2] Womens Canc Ctr, Palo Alto, CA 94304 USA
关键词
D O I
10.1006/gyno.2001.6312
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The purpose of this survey was to determine the range of surgical objectives, strategies, and outcomes of primary cytoreductive operations performed by gynecologic oncologists. Methods. A survey addressing the definition of "optimal" cytoreduction, the use of neoadjuvant chemotherapy, disease sites precluding optimal cytoreduction, reasons optimal cytoreduction or cytoreduction to a visibly disease-free outcome is or is not accomplished, the use of 15 specific operative procedures, and attitude toward postfellowship training in the surgical management of advanced stage epithelial ovarian cancer was mailed to candidate and full members of the Society of Gynecologic Oncologists. Analysis of discrete and binomial data utilized the chi (2) and independent samples t tests. Logistic regression confirmed relationships between responses and both the definition of optimal cytoreduction and the attitudes toward postfellowship training. Results. Three hundred ninety-three (61.4%) of 640 physicians provided utilizable data. A median of 95% of patients were reported to be operated on primarily and 5% were treated with neoadjuvant chemotherapy (P < 0.0001). A median of 9 (range 0-15) of the surveyed procedures were utilized. Forty-seven (12.0%) respondents defined optimal cytoreduction as no residual disease, 54 (13.7%) used a 5-mm threshold, 239 (60.8%) used a 1-cm threshold, and 48 (12.6%) utilized a 1.5- to 2.0-cm threshold. Small dimensions of residual disease (0-5 mm versus 1-2 em) defined optimal cytoreduction for physicians indicating that fewer disease sites precluded optimal cytoreduction (P = 0.02), using a larger number of the surveyed procedures (P = 0.04), and in practice longer (P = 0.001). Three hundred seventeen (83.9%) of 378 respondents favored development of postfellowship training in cytoreductive surgery. Physicians against postfellowship training used fewer of the surveyed procedures because of concerns about efficacy (P = 0.01). More recent fellowship graduates favored postfellowship training (P = 0.01). Conclusions. A range of surgical objectives, strategies, procedures used, and outcomes exists among gynecologic oncologists. Confirmation of the efficacy of cytoreductive surgery may cultivate a consensus about the most appropriate therapeutic objective and strategy for advanced ovarian cancer. Cooperative efforts should be undertaken to offer postfellowship training. (C) 2001 Academic Press.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 30 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   REVERSE HYSTEROCOLPOSIGMOIDECTOMY (RHCS) FOR RESECTION OF PANPELVIC TUMORS [J].
BARNES, W ;
JOHNSON, J ;
WAGGONER, S ;
BARTER, J ;
POTKUL, R ;
DELGADO, G .
GYNECOLOGIC ONCOLOGY, 1991, 42 (02) :151-155
[3]   The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma [J].
BenedettiPanici, P ;
Maneschi, F ;
Scambia, G ;
Cutillo, G ;
Greggi, S ;
Mancuso, S .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (04) :532-538
[4]  
BENEDETTIPANICI P, 1991, INT J GYNECOL CANCER, V133, P1
[5]   ELECTROSURGICAL DEBULKING OF OVARIAN-CANCER - A NEW TECHNIQUE USING THE ARGON BEAM COAGULATOR [J].
BRAND, E ;
PEARLMAN, N .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :115-118
[6]   Critique of surgical cytoreduction in advanced ovarian cancer [J].
Covens, AL .
GYNECOLOGIC ONCOLOGY, 2000, 78 (03) :269-274
[7]  
DEPE G, 1986, GYNECOL ONCOL, V24, P258
[8]  
DEPE G, 1990, OBSTET GYNECOL, V76, P1140
[9]   DEBULKING SURGERY FOR OVARIAN-CANCER WITH THE CAVITRON ULTRASONIC SURGICAL ASPIRATOR (CUSA) - A PRELIMINARY-REPORT [J].
DEPPE, G ;
MALVIYA, VK ;
MALONE, JM .
GYNECOLOGIC ONCOLOGY, 1988, 31 (01) :223-226
[10]   PERITONEAL IMPLANT ELIMINATION DURING CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER - IMPACT ON SURVIVAL [J].
EISENKOP, SM ;
NALICK, RH ;
WANG, HJ ;
TENG, NNH .
GYNECOLOGIC ONCOLOGY, 1993, 51 (02) :224-229